Entera Bio ($ENTX) Climbed 60% After $275M Private Placement — Scored 73/100 at 8:30 AM ET
ENTX stock climbed 60% after announcing an oversubscribed $275M private placement. RTPR scored the release 73/100 at 8:30 AM ET.
Entera Bio (NASDAQ: ENTX) stock is up today after the company announced pricing of an oversubscribed $275 million private placement, climbing as much as 60% from its price when the release crossed the wire. RTPR assigned the release an impact score of 73/100 at 8:30 AM ET, when the stock traded at $2.40.
What the release announced
According to the press release (free account required), Entera Bio priced an oversubscribed $275 million private placement led by BVF Partners. The proceeds will fund Phase 3 studies for the company's oral PTH peptide osteoporosis treatment.
What the stock did
Following the announcement, ENTX traded from $2.40 to a session high of $3.85, a gain of about 60%.
Historical context
This release received an impact score of 73/100.
- Releases scoring 60-80 produced a 15%+ move 21% of the time.
- Sample size: 648 settled outcomes over the past 90 days.
- Historical observations only, not predictions. Full band-by-band table on the impact scoreboard.
Timeline
- 8:30:00 AM ET — press release crossed the wire
- +382 ms — RTPR delivered the release
- 8:30:35 AM ET — impact score written: 73/100
- $2.40 — price at publication
- $3.85 — intraday high (60% above the price at publication)
Real-time impact scores on every press release are part of RTPR Pro. Impact scores are in beta; historical tendencies, not predictions or investment advice.